MX2022011904A - Aminociclobutanos como moduladores de monoacilglicerol lipasa. - Google Patents
Aminociclobutanos como moduladores de monoacilglicerol lipasa.Info
- Publication number
- MX2022011904A MX2022011904A MX2022011904A MX2022011904A MX2022011904A MX 2022011904 A MX2022011904 A MX 2022011904A MX 2022011904 A MX2022011904 A MX 2022011904A MX 2022011904 A MX2022011904 A MX 2022011904A MX 2022011904 A MX2022011904 A MX 2022011904A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- disorders
- aminocyclobutanes
- methods
- monoacylglycerol lipase
- Prior art date
Links
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical class NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 title abstract 2
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 title 1
- 108020002334 Monoacylglycerol lipase Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- -1 isotopes Chemical class 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Los compuestos de aminociclobutano de la Fórmula (I), y sales, isótopos, N-óxidos, solvatos y estereoisómeros farmacéuticamente aceptables de estos, composiciones farmacéuticas que los contienen, y métodos para usarlos incluyen métodos para tratar estados de enfermedad, trastornos, y afecciones asociadas con la modulación de la MGL, tales como los asociados con dolor, trastornos psiquiátricos, trastornos neurológicos (que incluyen, pero no se limitan a, trastorno depresivo severo, depresión resistente al tratamiento, depresión ansiosa, trastornos del espectro autista, síndrome de Asperger, trastorno bipolar), cánceres y afecciones oculares: en donde X, R1, R2a, R2b, R3 Y R4 se definen en la presente descripción.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000298P | 2020-03-26 | 2020-03-26 | |
| PCT/EP2021/057838 WO2021191391A1 (en) | 2020-03-26 | 2021-03-25 | Aminocyclobutanes as monoacylglycerol lipase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011904A true MX2022011904A (es) | 2023-01-04 |
Family
ID=75302571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011904A MX2022011904A (es) | 2020-03-26 | 2021-03-25 | Aminociclobutanos como moduladores de monoacilglicerol lipasa. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11512059B2 (es) |
| EP (1) | EP4126825A1 (es) |
| JP (1) | JP2023518556A (es) |
| KR (1) | KR20220158785A (es) |
| CN (1) | CN115335365B (es) |
| AU (1) | AU2021240349A1 (es) |
| BR (1) | BR112022019178A2 (es) |
| CA (1) | CA3176113A1 (es) |
| MX (1) | MX2022011904A (es) |
| WO (1) | WO2021191391A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022009804A (es) | 2020-02-10 | 2022-09-02 | Janssen Pharmaceutica Nv | Moduladores de la monoacilglicerol lipasa. |
| AU2021240349A1 (en) | 2020-03-26 | 2022-09-29 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
| US11505546B2 (en) | 2020-03-26 | 2022-11-22 | Janssen Pharmaceutica Nv | Azaspirocycles as monoacylglycerol lipase modulators |
| AU2021243726A1 (en) | 2020-03-26 | 2022-09-29 | Janssen Pharmaceutica Nv | Aryl piperidines as monoacylglycerol lipase modulators |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135508A1 (en) | 2002-07-25 | 2006-06-22 | Manuela Villa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| TW201105655A (en) * | 2009-04-22 | 2011-02-16 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| US8435977B2 (en) | 2009-04-22 | 2013-05-07 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
| US8575363B2 (en) * | 2010-10-22 | 2013-11-05 | Janssen Pharmaceutica N.V. | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors |
| JP2014528428A (ja) | 2011-09-30 | 2014-10-27 | ヤンセン ファーマシューティカ エヌ．ベー． | 代謝症及び関連障害の治療のためのモノアシルグリセロールリパーゼ阻害剤 |
| JP6832342B2 (ja) | 2016-03-31 | 2021-02-24 | 武田薬品工業株式会社 | 複素環化合物 |
| DK3436444T3 (da) | 2016-03-31 | 2020-07-27 | Takeda Pharmaceuticals Co | Heterocyklisk forbindelse |
| WO2018089355A1 (en) * | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors |
| SG11201906427QA (en) * | 2017-01-23 | 2019-08-27 | Pfizer | Heterocyclic spiro compounds as magl inhibitors |
| BR112020005720A2 (pt) | 2017-09-29 | 2020-10-20 | Takeda Pharmaceutical Company Limited | composto ou sal, medicamento, métodos para inibir monoacilglicerol lipase e para a profilaxia ou o tratamento de doença de alzheimer, doença de parkinson, doença de huntington, esclerose lateral amiotrófica, esclerose múltipla, distúrbio de ansiedade, dor, epilepsia ou depressão, e, uso do composto ou sal. |
| US10662159B2 (en) * | 2017-11-22 | 2020-05-26 | Makscientific, Llc | ABHD6 and dual ABHD6/MGL inhibitors and their uses |
| RU2769507C1 (ru) * | 2018-08-13 | 2022-04-01 | Ф. Хоффманн-Ля Рош Аг | Новые гетероциклические соединения как ингибиторы моноацилглицеринлипазы |
| WO2020211798A1 (zh) | 2019-04-16 | 2020-10-22 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
| MX2022009804A (es) | 2020-02-10 | 2022-09-02 | Janssen Pharmaceutica Nv | Moduladores de la monoacilglicerol lipasa. |
| AU2021243726A1 (en) | 2020-03-26 | 2022-09-29 | Janssen Pharmaceutica Nv | Aryl piperidines as monoacylglycerol lipase modulators |
| US11505546B2 (en) | 2020-03-26 | 2022-11-22 | Janssen Pharmaceutica Nv | Azaspirocycles as monoacylglycerol lipase modulators |
| AU2021240349A1 (en) | 2020-03-26 | 2022-09-29 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
-
2021
- 2021-03-25 AU AU2021240349A patent/AU2021240349A1/en active Pending
- 2021-03-25 US US17/212,302 patent/US11512059B2/en active Active
- 2021-03-25 EP EP21715558.9A patent/EP4126825A1/en active Pending
- 2021-03-25 KR KR1020227037062A patent/KR20220158785A/ko active Search and Examination
- 2021-03-25 BR BR112022019178A patent/BR112022019178A2/pt unknown
- 2021-03-25 MX MX2022011904A patent/MX2022011904A/es unknown
- 2021-03-25 JP JP2022557641A patent/JP2023518556A/ja active Pending
- 2021-03-25 WO PCT/EP2021/057838 patent/WO2021191391A1/en unknown
- 2021-03-25 CA CA3176113A patent/CA3176113A1/en active Pending
- 2021-03-25 CN CN202180024377.9A patent/CN115335365B/zh active Active
-
2022
- 2022-10-31 US US18/051,145 patent/US11919870B2/en active Active
-
2024
- 2024-03-01 US US18/593,601 patent/US20240208914A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115335365B (zh) | 2024-06-18 |
| KR20220158785A (ko) | 2022-12-01 |
| EP4126825A1 (en) | 2023-02-08 |
| CN115335365A (zh) | 2022-11-11 |
| WO2021191391A1 (en) | 2021-09-30 |
| US20240208914A1 (en) | 2024-06-27 |
| US11512059B2 (en) | 2022-11-29 |
| US20210317094A1 (en) | 2021-10-14 |
| AU2021240349A1 (en) | 2022-09-29 |
| US11919870B2 (en) | 2024-03-05 |
| BR112022019178A2 (pt) | 2022-11-01 |
| US20230331686A1 (en) | 2023-10-19 |
| CA3176113A1 (en) | 2021-09-30 |
| JP2023518556A (ja) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011904A (es) | Aminociclobutanos como moduladores de monoacilglicerol lipasa. | |
| MX2022011903A (es) | Azaspirociclos como moduladores de monoacilglicerol lipasa. | |
| MX2022011902A (es) | Moduladores de la monoacilglicerol lipasa. | |
| MX2022011901A (es) | Arilo piperidinas como moduladores de monoacilglicerol lipasa. | |
| CR20220376A (es) | Moduladores de la monoacilglicerol lipasa | |
| CR20210153A (es) | Moduladores de monoacilglicerol lipasa | |
| MX2023003240A (es) | Moduladores de monoacilglicerol lipasa de ciclobutilamida. | |
| MX2021003661A (es) | Moduladores de la monoacilglicerol lipasa. | |
| MX2022015613A (es) | Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental. | |
| MX2022013647A (es) | Imidazopiridazinas como moduladores de il-17. | |
| MX2024001839A (es) | Moduladores de monoacilglicerol lipasa para uso en trastornos del espectro autista. | |
| JP2017503025A (ja) | 神経形成を刺激することができるｎ−フェニル−ラクタム誘導体及び神経障害の処置におけるそれらの使用 | |
| PH12019501968A1 (en) | PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | |
| MX2023009285A (es) | Compuestos novedosos. | |
| RU94039284A (ru) | Производные пиперазина, способ их получения, фармкомпозиция и ее использование | |
| ZA202301873B (en) | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | |
| WO2023115060A1 (en) | Psychoplastogens for treating hearing-related disorders | |
| MX2023011991A (es) | Moduladores de receptor 1 asociado a las aminas trazas (taar1) y serotonina, y composiciones farmacéuticas, y métodos de uso de estos. | |
| WO2022204344A3 (en) | Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents | |
| JP2004527562A (ja) | ニコチン性アセチルコリンレセプターリガンドおよび／またはセロトニン作動性リガンドとしての６Ｈ−オキサゾロ［４，５−ｅ］インドール誘導体 | |
| MX2023003165A (es) | Moduladores de la caseína cinasa 1 delta. | |
| KR890006653A (ko) | 헤테로사이클릭 화합물 및 이의 제조방법 및 용도 | |
| WO2024108179A3 (en) | 2-ethylamine substituted benzofuran and benzothiophene compositions for mental disorders or enhancement | |
| WO2019109132A1 (en) | Isoxazolyl compounds as receptor modulating compounds and methods and uses thereof | |
| MX2023003170A (es) | Moduladores de la caseina cinasa 1 delta. |